Building for the Future: Why Eramol is Investing in a New Sterile Manufacturing Facility

(Eramol- Sevenoaks, UK, Wednesday 10th September 2025).

The demand for sterile manufacturing capacity is accelerating. Biotechs, virtual pharma, and healthcare providers are under increasing pressure to deliver safe, compliant, and cost-effective therapies at speed. For many, access to the right partner with both flexibility and regulatory robustness is the difference between trial success and costly delay.

At Eramol, we recognised this challenge early — and committed to building a purpose-designed sterile facility that meets the most stringent global standards while offering the agility required for small to medium batch production.

Our new 1,900 sq. ft sterile cleanroom suite sits within an 11,000 sq. ft facility that also houses offices, reception, and warehouse space. It has been engineered to align with the latest EU GMP Annex 1 requirements (2023), incorporating aseptic filtration and terminal sterilisation technologies and single-use systems to reduce cross-contamination risk and minimise bioburden.

The value for clients:

• Regulatory confidence: 100% dose testing, container closure integrity testing and in-batch controls

• End-to-end services: From manufacture, through to packaging, labelling, QP release and global cold chain distribution

• Efficiency: Designs that minimise product loss and maximise yield

• Speed to clinic: Flexible batch sizes, early phase support, and rapid project onboarding

"Our vision is to build more than just capacity — we’re building confidence for our partners. This facility has been designed from the ground up to reflect best practice in sterile manufacturing while maintaining the agility to support smaller, innovative companies. It’s about combining speed, compliance, and reliability so that breakthrough therapies can reach patients without unnecessary barriers,"
— Peter Mollison & Eric Che, Co Founders & CEOs, Eramol

By investing now, Eramol is future-proofing sterile manufacturing capacity to serve innovators through 2026 and beyond — helping ensure that promising therapies reach patients faster, safer, and more reliably.